baber/WOPTO huggingface dataset:
Patent NZ-570625-A (NZ)
Title: Treatment of duchenne muscular dystrophy
Inventor: WYNNE GRAHAM MICHAEL
IPC: A61K31/426
Filed: 2007-02-09
Abstract: Disclosed is the use of a compound of Formula (I) e.g. 5-(ethylsulfonyl)-2-(naphthalene-2-yl)benzo[d]oxazole in which A1, A2, A3 and A4, which may be the same or different, represent CR1, wherein R1 represents: nitro, halogen, amino or (alkylamino or dialkyl amino ; Y represents N and X represents O, R9 represents - L -R3, in which L is a single bond and R3 is an aromatic mono- or bi-cyclic system; or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy or Becker muscular dystrophy.
Patent NZ-570762-A (NZ)
Title: A wound dressing
Inventor: MOUTON JACOBUS FREDERICK
IPC: A61F13/00
Filed: 2006-03-31
Abstract: Disclosed is a wound dressing (10). The wound dressing includes first and second absorbent layers (12, 14) of a non-woven fabric of viscose and polyester fibres. Each absorbent layer has an operatively inner face (20, 26) and an operatively outer face (18, 22). The first and the second absorbent layers are bonded together with their operatively inner faces in face-to-face relationship, such that the absorbent layers together form a pad. The bonding between the first and second absorbent layers is put into effect by means of a needle-punching process in which the needle punching density is no more than 400 punches/cm2. The wound dressing further includes a third layer (16) sandwiched between and bonded to the first and second absorbent layers. The third layer is in the form of cotton gauze.
Patent NZ-571427-A (NZ)
Title: Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
Inventor: D AMOUR KEVIN
IPC: C12N5/071
Filed: 2007-03-02
Abstract: Disclosed is in vitro cell culture comprising human cells wherein at least 5% of said human cells are endocrine precursor cells that express a marker selected from the group consisting of neurogenin 3 (NEUROG3), paired box 4 (PAX4) and NKX2 transcription factor related locus 2 (NKX2.2), said endocrine precursor cells being multipotent cells that can differentiate into pancreatic islet hormone-expressing cells that express at least one pancreatic hormone selected from the group consisting of insulin, somatostatin, ghrelin, pancreatic polypeptide and glucagon. Also disclosed is an in vitro method of producing endocrine precursor cells, said method comprising the steps of: (a) providing a cell population comprising pluripotent human cells with a TGF-beta superfamily growth factor, thereby producing definitive endoderm cells; (b) withdrawing TGF beta superfamily from said cell population; (c) providing said cell population with a retinoid, thereby producing human PDX1-positive pancreatic endoderm cells; and (d) incubating said cell population in a culture medium for sufficient time to permit formation of human endocrine precursor cells expressing neurogenin 3 (NEUROG3).
Patent NZ-573093-A (NZ)
Title: Insulinotropic peptide synthesis
Inventor: CHEN LIN
IPC: C07K14/605
Filed: 2007-06-19
Abstract: Disclosed is a method of making an insulinotropic peptide, comprising the following steps of a) to f): a) providing a first peptide fragment including the amino acid sequence HX8EX10 (SEQ ID NO.6), wherein X8 and X10 are each residues of an achiral amino acid, each of H and E optionally including side chain protection; b) providing a second peptide fragment including the amino acid sequence TFTSDVXI7-18YLEG (SEQ ID NO.8) wherein the residue denoted by the symbol XI7-18 is a dipeptide residue of a pseudoproline, said amino acid residues of the sequence optionally including side chain protection; c) coupling the first fragment to the second fragment to provide a third peptide fragment including the amino acid sequence HX8EX10 TFTSDVXI7-18YLEG (SEQ ID NO. 11), said amino acid residues of the sequence optionally including side chain protection; d) providing a fourth peptide fragment including the amino acid sequence QAAKEFIAWLVKX35 (SEQ ID NO.9), wherein X35 is a residue of an achiral amino acid, said amino acid residues of the sequence optionally including side chain protection; e) coupling the fourth peptide fragment to arginine in order to provide a fifth peptide fragment including the amino acid sequence QAAKEFIAWLVK X35R (SEQ ID NO. 12), said residues of the sequence optionally including side chain protection; and f) coupling the fifth fragment to the third fragment in order to provide an insulinotropic peptide including the amino acid sequence HXSEXIOTFTSDVXI7-18 YLEGQAAKEFIAWLVK X35R (SEQ ID NO. 13), said residues of the sequence optionally including side chain protection.
Patent NZ-578664-A (NZ)
Title: Extended release formulation of nevirapine
Inventor: CAPPOLA MICHAEL L
IPC: A61K9/20
Filed: 2008-06-04
Abstract: Disclosed herein is a pharmaceutical composition in the form of a tablet which; (a) comprises 300 mg or 400 mg of nevirapine in an extended release matrix and which, when administered as a single-dose to a fasting human, wherein the extended release matrix comprises a hydrophilic polymer selected from hydroxypropylmethylcellulose (HPMC, hypromellose), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), xanthan gum, sodium alginate, polyethylene oxide, and crosslinked homopolymers and copolymers of acrylic acid, or a mixture thereof, which exhibits a single-dose fasting Tmax of 10 to 48 hr; which exhibits a Cmax,ss/Cmin,ss which is in the range of 1.1 to 2, measured during multiple-dosing; and which has an in-vitro dissolution profile such that at least 2% w/w and no more than 30% w/w of the nevirapine is released at 2 hours; at least 20% w/w and up to 100% w/w of the nevirapine is released at 8 hours; at least 40% w/w and and up to 100% w/w of the nevirapine is released at 14 hours, when dissolution is measured by the USP Paddle Method at 50 rpm at a volume of 900 mL aqueous buffer containing 6% w/w of sodium lauryl sulfate, having a pH of 6.8 at 37°C wherein a 300mg desirably exhibits (1) a geometric mean Cmax of 1,000 to 2,300 ng/mL; and (2) a geometric mean AUC0-? of 73,400 to 178,100 hr(ng/mL); and which, when administered in multiple doses to a fasting human, exhibits (1) a geometric mean Cmax, ss of 2,300 to 3,700 ng/mL; and (2) a geometric mean AUC0-24, ss of 45,000 to 75,000 hr(ng/mL); or And for a 400mg dose exhibits: (1) a geometric mean Cmax of 1,210 to 2,740 ng/mL; and (2) a geometric mean AUCO-? of 109,000 to 237,000 hr(ng/mL); and which, when administered in multiple doses to a fasting human, exhibits (1) a geometric mean Cmax, ss of 3,100 to 4,900 ng/mL; and (2) a geometric mean AUC0-24, ss of 60,000 to 99,000 hr(ng/mL). Also disclosed in a tablet pharmaceutical dosage form wherein each table comprises: (a) 400 mg of anhydrous nevirapine; (b) 270 mg of Hypromellose 2208; (c) 400 mg of lactose monohydrate; and (d) 10 mg of Magnesium stearate; wherein each tablet is compressed by a force of 10-25 kN.
Patent NZ-579084-A (NZ)
Title: Solid forms of { 1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl} -(4-trifluromethyl-phenyl)amine
Inventor: HASHASH AHMAD
IPC: A61K31/4184
Filed: 2008-02-28
Abstract: Disclosed is a solid form of 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine. The solid form is used to treat cancer.
Patent NZ-582780-A (NZ)
Title: Desalination of brine using a rotating kiln
Inventor: DAVEY GARTH
IPC: B01D1/00
Filed: 2008-06-17
Abstract: Disclosed is a desalination process in which brine is boiled in a rotating kiln to form steam and a salt residue, the steam is condensed to pure water in the same kiln, and the salt residue is removed from the base of the kiln. The brine may be sprayed against the wall structure of the rotary kiln, and a scraper may be used to remove the salt. Also disclosed is a kiln for a desalination plant comprising a hollow wall with a tapered base, the kiln containing a brine infeed comprising a plurality of vertically spaced nozzles, the nozzles being arranged to direct brine against an inner wall of the kiln, a scraper positioned adjacent the inner wall of the kiln and means to cause axial rotation of the kiln.
Patent NZ-584431-A (NZ)
Title: Floor panel support pedstals, where the pedstals have clips with slots for receiving stringer clips
Inventor: ZLATAR PETAR
IPC: E04F15/024
Filed: 2008-08-04
Abstract: An air tight panel support assembly for an access floor having a plurality of panels includes a pedestal 60 for supporting at least one panel of the access floor, and a stringer 66 supported by the pedestal 60. In use, the stringer 66 extends from one pedestal to another pedestal and supports the underside edges of adjacent panels so as to close any gap there between. The stringer 66 has sealing material 72 at its upper side for providing an air tight seal against the underside edges of adjacent floor panels, and is formed as a substantially U-shaped channel 68 between the clips 70 at either end. Each pedestal 60 has a platform upon which the corners of the panels are received, a cruciform boss 28 and a cruciform divider panel 32 having noise attenuation and vibration dampening properties. The divider panel 32 is secured upon the cruciform boss 28, and receives thereupon the corner of one or more floor panels. Slots 64 are formed in the head portion of the pedestal 60 and the openings of the slots 64 are sunk below the cruciform divider panel 32 so that, when a clip 70 of a stringer 66 releasably engages a slot 64, the stringer 66 will be flush mounted on the pedestal 60.
Patent NZ-586435-A (NZ)
Title: Cream cheese and method of manufacture
Inventor: WOLFSCHOON-POMBO ALAN FREDERICK
IPC: A01J25/00
Filed: 2010-06-25
Abstract: Disclosed is a method of making a cream cheese product comprising the steps of: providing a standardized milk base having about 80% to about 100% of a milk source and 0% to about 20% of a fat source, wherein the milk source has less than or equal to 7% fat, wherein the fat source has less than 60% fat, and wherein the standardized milk base has a first fat content of less than or equal to 7%; fermenting the standardized milk base with a bacteria culture to form a fermented milk base; ultrafiltrating the fermented milk base to form a retentate and a permeate, wherein the retentate has a second fat content greater than the first fat content and less than or equal to 20%; providing a sour cream with a third fat content greater than 20%; and mixing the retentate and the sour cream to form the cream cheese product, wherein the first fat content and amount of retentate and the third fat content and amount of sour cream are effective to form the cream cheese product with a total fat content greater than 20%. Also disclosed is a cream cheese produced by this method.
Patent NZ-586754-A (NZ)
Title: Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
Inventor: HARRIS REED J
IPC: A61P35/00
Filed: 2009-01-28
Abstract: Disclosed is a composition comprising a main species HER2 antibody that binds to domain II of HER2, and an acidic variant thereof comprising a disulfide reduced variant and/or a non-reducible variant of the main species antibody.
Patent NZ-590570-A (NZ)
Title: Process for the preparation of opioid modulators
Inventor: CAI CHAOZHONG
IPC: C07D211/60
Filed: 2006-03-06
Abstract: The disclosure relates to processes for the preparation of opioid modulators (agonists and antagonists) represented by formula (I) and intermediates in their synthesis. Particularly disclosed is a process for the preparation of 2-tert-Butoxycarbonylamino-3-(4-carbamoyl-2,6-dimethyl-phenyl) propionic acid. These opioid modulators are useful for the treatment and prevention of as pain and gastrointestinal disorders.
Patent NZ-590871-A (NZ)
Title: Recombinant fibrinogen
Inventor: BOUT ABRAHAM
IPC: C07K14/75
Filed: 2009-07-09
Abstract: Disclosed are nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain for insertion into a cell line. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system. The cells produce intact recombinant fibrinogen at a level of at least 3 picograms per cell per day. Antibodies for selection of a cell line with the desired traits are also disclosed.
Patent NZ-592774-A (NZ)
Title: Pilot bit
Inventor: BOAKES MAURICE DESMOND
IPC: E02F3/06
Filed: 2009-09-03
Abstract: 592774 A pilot bit 20 for an earth excavating device 10 comprising an elongate body 25 having a proximal end 27 adapted for coupling to a rotating shaft 11 of the earth excavating device 10 and a distal end 23. A plurality of blades 21 extend radially from and being substantially equidistantly spaced about the elongate body 25 such that each blade 21 extends in a spiral at least partially along a length of the elongate body 25. At least one of the blades 21 has a plurality of cutting faces 26, 28 formed therein at predetermined distances along a length thereof. Each cutting face having a cutting edge that extends substantially perpendicular to a longitudinal axis of the elongate body 25 so as to define a plurality of cutting planes
Patent NZ-592907-A (NZ)
Title: Piperazine salt and a process for the preparation thereof
Inventor: CZIBULA LASZLO
IPC: C07D295/135
Filed: 2009-12-17
Abstract: 592907 Disclosed is a process for the preparation of trans N-{ 4-{ 2-[4-(2,3-dichlorophenyl)-piperazine-1-il]-ethyl} -cyclohexylamine dihydrochloride monohydrate wherein a) reacting trans 2-{ 1-[4-(N-tert-butoxycarbonyl)amino]-cyclohexyl} -acetic acid ester with sodium borohydride and aluminium trichloride to give trans 2-{ 1-[4-(N-tert-butoxycarbonyl)-amino]-cyclohexyl} -ethanol; b) reacting trans 2-{ 1-[4-(N-tert-butoxycarbonyl)-amino]cyclohexyl} -ethanol obtained with methanesulfonic acid chloride in the presence of an acid binding agent to give trans 2-{ 1-[4-(N-tert-butoxycarbonyl)-amino]-cyclohexyl} -ethyl methanesulfonate; c) reacting trans 2-{ 1-[4-(N-tert-butoxycarbonyl)-amino]-cyclohexyl} -ethyl methanesulfonate obtained with 2,3-dichlorophenyl-piperazine in the presence of an acid binding agent to give trans N-{ 4-{ 2-[4-(2,3-dichlorophenyl)piperazine-1-il]-ethyl} -cyclohexylamine; d) heating trans N-{ 4-{ 2-[4-(2,3-dichlorophenyl)piperazine-1-il]-ethyl} -cyclohexylamine obtained to a temperature between 40-100?C in a mixture of aqueous hydrochloric acid/methanol to give trans N-{ 4-{ 2-[4-(2,3-dichlorophenyl)piperazine-1-il]-ethyl} -cyclohexylamine dihydrochloride monohydrate. Also disclosed is Trans N-{ 4-{ 2-[4-(2,3-dichlorophenyl)-piperazine-1-il]-ethyl} -cyclohexylamine dihydrochloride monohydrate.
Patent NZ-594758-A (NZ)
Title: Network based ambient services
Inventor: RALEIGH GREGORY G
IPC: H04W4/24
Filed: 2010-01-18
Abstract: 594758 Disclosed is a method for accounting for service usage performed by a network system operated by a network operator. The method includes monitoring traffic over a wireless access network, which communicatively couples the network system to an end-user device. The end-user device includes a plurality of applications, each of the plurality of applications enabling the end-user device to access, over the wireless access network, at least one of one or more network end points. A first application of the plurality of applications enables the end-user device to access a particular network end point of the one or more network end points, the particular network end point being outside of the wireless access network and operated by or on behalf of one or more entities other than the network operator. The method also includes identifying, within the traffic over the wireless access network, one or more data transfers associated with access to the particular network end point by the first application. The method also includes obtaining an offset, the offset being based on a use of the wireless access network for the one or more data transfers associated with access to the particular network end point by the first application; and allocating at least a portion of the offset to a first account. The first account is associated with a service sponsor responsible for paying for or subsidising at least a portion of the use of the wireless access network for the one or more data transfers associated with access to the particular network end point by the first application. The service sponsor is not a user or a subscriber associated with the end-user device.
Patent NZ-595696-A (NZ)
Title: Novel composite materials comprising a thermoplastic matrix polymer and wood particles
Inventor: PARSSINEN ANTTI
IPC: A61L15/10
Filed: 2010-03-11
Abstract: 595696 Disclosed herein is a temperature thermoplastic wood-biopolymer composite comprising a first component formed by a polymer and a second component formed by a reinforcing material, wherein the first component comprises a thermoplastic polymer selected from the group of biodegradable polymers and mixtures thereof, and the second component comprises a woody material of platy wood particles having a smallest dimension greater than 0.1 mm. The material is made from a thermoplastic composite that softens when heated to approximately 60 ºC, after which it can be formed directly on the patient. The composite then retains its shape as it cools down. In one embodiment the material is composed of epsilon caprolactone homopolymer reinforced with discontinuous short length wood particles.
Patent NZ-596564-A (NZ)
Title: Rotary cassette system for dry powder inhaler with blister packs, a vibrating element and a piercing element
Inventor: MOSIER KENT D
IPC: A61M15/00
Filed: 2010-05-21
Abstract: A dry powder inhaler, comprising a vibrating element, a piercing element, a cartridge attached containing a plurality of individually addressable blister packs, and a lever arm. Each of the plurality of individually addressable blister packs is detachable from the cartridge and contains a specified amount of powdered medicament. The blister packs are arranged in a circular formation. The movement of the lever arm causes a selected blister pack to be dragged between the vibrating element and the piercing element to be deaggregated and inhaled by a user.
Patent NZ-597819-A (NZ)
Title: Optical sensor for a robotic arm with a light source, segmented mirror ring and a camera
Inventor: HJORNET PREBEN K
IPC: B25J19/02
Filed: 2008-04-25
Abstract: An optical system 100 for determining a location and orientation of a work-piece on a work surface 114, comprises a circular array of light sources 146 mounted above the work surface 114, at least one segmented ring 170 of mirrors 148 mounted below the circular array of light sources 146 and above the work surface 114, and a camera 144 having an objective lens for recording an image of the work piece. The circular array of light sources 146 directs light downward and outward toward the at least one segmented ring 170 of mirrors 148, and the at least one segmented ring 170 of mirrors 148 reflects the light downward and inward toward the work surface 114 to provide uniform illumination around the circumference of the work-piece.
Patent NZ-604495-A (NZ)
Title: Rebar clip for joining different size bars
Inventor: KODI JON R
IPC: F16B2/22
Filed: 2011-06-01
Abstract: A rebar clip for joining a larger diameter rebar (12) to a smaller diameter rebar (14) transverse to the larger diameter rebar is disclosed. The rebar clip includes diameter reducing tabs (Fig 1: 42, 44) extending into one of lower (Fig 1: 22, 24) and upper (Fig 1: 38, 40) pairs of lateral openings to engage the rebars. A tool for attaching the clips using a string of frangible connected clips is also disclosed.
Patent NZ-607965-A (NZ)
Title: Removable rotor blade tip
Inventor: OLTHOFF GERHARD
IPC: F03D1/06
Filed: 2011-09-01
Abstract: A rotor blade tip (100) for a rotor blade (200), in particular for a rotor blade of a wind energy installation, which is in the form of an autonomous part which can be connected to the rotor blade (200), and has a first connecting surface, which is directed in the direction of the rotor blade to be connected. In order to produce the connection to the rotor blade (200), first guide means (110), having a guide direction (FR), for production of the connection to the rotor blade (200), as well as first locking means (120) for attachment of the rotor blade tip (100) to the rotor blade (200), are provided on the connecting surface, as first components of a connecting mechanism. In particular for a wind energy installation, the rotor blade (200) consists of a rotor blade body having an aerodynamic profile (204), which has a pressure side (204.2) and a suction side (204.1), a rotor blade root at a first end of the rotor blade body (206) and of the rotor blade tip (100) at a second end, opposite the first end, wherein, for the connection to the rotor blade tip (100), the rotor blade body (206) has second components of the connecting mechanism which contain second guide means (210), which are complementary to the first guide means (110) of the rotor blade tip (100), as well as second locking means (220), which interact with the first locking means (120) of the rotor blade tip (100). The tip may curve in the direction of the pressure side and may also be rotated around the thread axle to reduce the noise produced by the turbine.
Patent NZ-616789-A (NZ)
Title: Acute cognitive and mood effects of plant polysaccharides in adult human subjects
Inventor: BEST TALITHA
IPC: A61P25/00
Filed: 2012-04-24
Abstract: Discloses a method for improving cognition, reducing stress, anxiety, mental-fatigue, or any combinations thereof in a healthy human subject comprising the steps of: selecting the healthy human subject in need of improvement of at least one of cognition, reduction of stress, anxiety, or mental-fatigue, or any combinations thereof, wherein the subject has been previously identified as needing improvement in at least one of cognition, reduction of stress, anxiety, or mental-fatigue; and administering a nutritionally effective amount of a dietary supplement in an amount sufficient to improve at least one of cognition, reduce stress, anxiety, or mental-fatigue, or any combinations thereof; wherein the dietary supplement comprises a nutritionally effective amount of isolated and purified acetylated mannose, and a nutritionally effective amount of at least five isolated and purified saccharides selected from the group consisting of: galactose, glucose, mannose, xylose, N-acetylneuraminic acid, fucose, N-acetylgalactosamine, N-acetylglucosamine, arabinose, glucuronic acid, galacturonic acid, iduronic acid and arabinogalactan.